Health & Wellness
Black-ownedPeople of Color
Corvidane
Developing a novel, safe drug to prevent heart attacks, strokes, and liver transplants.
New York,
NY
Investment type:
Equity
(SAFE)
Target raise:
$250,000
- $618,000
Minimum investment:
$100
$100
End date:
Nov 01, 2023
Nov 01, 2023
ended
Share
Highlights
- CEO designed trials for Vascepa®, which reduces heart attack and stroke risk for high triglycerides.
- Corvidane raised $360k from over 200 Investors in previous RegCF.
- Corvidane granted ~$700k in non-dilutive grants for Research and Development.
- Results of Corvida’s effect on LDLr-/- mouse and genes associated with atherosclerosis due in 2023.
Our Story
Corvidane is developing a new approach to treat heart and liver diseases
Our Ambition
In 5 years, we anticipate we will be selling and/or or licensing our drug Corvida.